489 related articles for article (PubMed ID: 38112999)
1. Recent Advances of RNA m
Ma S; Barr T; Yu J
Cancer Treat Res; 2023; 190():49-94. PubMed ID: 38112999
[TBL] [Abstract][Full Text] [Related]
2. Cancer immunoediting and resistance to T cell-based immunotherapy.
O'Donnell JS; Teng MWL; Smyth MJ
Nat Rev Clin Oncol; 2019 Mar; 16(3):151-167. PubMed ID: 30523282
[TBL] [Abstract][Full Text] [Related]
3. Targeting RNA N
Li W; Hao Y; Zhang X; Xu S; Pang D
Mol Cancer; 2022 Sep; 21(1):176. PubMed ID: 36071523
[TBL] [Abstract][Full Text] [Related]
4. RNA N
Zhang Z; Zhang C; Luo Y; Zhang G; Wu P; Sun N; He J
Clin Transl Med; 2021 Sep; 11(9):e525. PubMed ID: 34586737
[TBL] [Abstract][Full Text] [Related]
5. Novel strategies for cancer immunotherapy: counter-immunoediting therapy.
Liu S; Sun Q; Ren X
J Hematol Oncol; 2023 Apr; 16(1):38. PubMed ID: 37055849
[TBL] [Abstract][Full Text] [Related]
6. Roles and therapeutic implications of m6A modification in cancer immunotherapy.
Pan J; Huang T; Deng Z; Zou C
Front Immunol; 2023; 14():1132601. PubMed ID: 36960074
[TBL] [Abstract][Full Text] [Related]
7. Targeting the RNA m
Li X; Ma S; Deng Y; Yi P; Yu J
Mol Cancer; 2022 Mar; 21(1):76. PubMed ID: 35296338
[TBL] [Abstract][Full Text] [Related]
8. [Cancer Immunoediting in the Development of Cancer Immunotherapy].
Ariyasu R; Nishikawa H
Gan To Kagaku Ryoho; 2019 Mar; 46(3):407-411. PubMed ID: 30914573
[TBL] [Abstract][Full Text] [Related]
9. Cancer Immunoediting in the Era of Immuno-oncology.
Gubin MM; Vesely MD
Clin Cancer Res; 2022 Sep; 28(18):3917-3928. PubMed ID: 35594163
[TBL] [Abstract][Full Text] [Related]
10. Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges.
Kunimasa K; Goto T
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963413
[TBL] [Abstract][Full Text] [Related]
11. Recent Advances in RNA m
Verghese M; Wilkinson E; He YY
Cancer Treat Res; 2023; 190():95-142. PubMed ID: 38113000
[TBL] [Abstract][Full Text] [Related]
12. Surmounting cancer drug resistance: New insights from the perspective of N
Li B; Jiang J; Assaraf YG; Xiao H; Chen ZS; Huang C
Drug Resist Updat; 2020 Dec; 53():100720. PubMed ID: 32892147
[TBL] [Abstract][Full Text] [Related]
13. Targeting RNA N6-methyladenosine to synergize with immune checkpoint therapy.
Zhou X; Li C; Chen T; Li W; Wang X; Yang Q
Mol Cancer; 2023 Feb; 22(1):36. PubMed ID: 36810108
[TBL] [Abstract][Full Text] [Related]
14. From Cancer Immunoediting to New Strategies in Cancer Immunotherapy: The Roles of Immune Cells and Mechanics in Oncology.
Aragon-Sanabria V; Kim GB; Dong C
Adv Exp Med Biol; 2018; 1092():113-138. PubMed ID: 30368751
[TBL] [Abstract][Full Text] [Related]
15. Have Cells Harboring the HIV Reservoir Been Immunoedited?
Huang SH; McCann CD; Mota TM; Wang C; Lipkin SM; Jones RB
Front Immunol; 2019; 10():1842. PubMed ID: 31447850
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic reprogramming of T cells: unlocking new avenues for cancer immunotherapy.
Singh V; Nandi S; Ghosh A; Adhikary S; Mukherjee S; Roy S; Das C
Cancer Metastasis Rev; 2024 Mar; 43(1):175-195. PubMed ID: 38233727
[TBL] [Abstract][Full Text] [Related]
17. Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors.
Wilczyński JR; Nowak M
Exp Suppl; 2022; 113():1-57. PubMed ID: 35165859
[TBL] [Abstract][Full Text] [Related]
18. N6-Methyladenosine RNA Modification in the Tumor Immune Microenvironment: Novel Implications for Immunotherapy.
Guo L; Yang H; Zhou C; Shi Y; Huang L; Zhang J
Front Immunol; 2021; 12():773570. PubMed ID: 34956201
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic applications of the cancer immunoediting hypothesis.
Desai R; Coxon AT; Dunn GP
Semin Cancer Biol; 2022 Jan; 78():63-77. PubMed ID: 33711414
[TBL] [Abstract][Full Text] [Related]
20. N
Dong S; Wu Y; Liu Y; Weng H; Huang H
Cancer Commun (Lond); 2021 Jul; 41(7):538-559. PubMed ID: 33955720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
